Home > Haematology > EHA 2019 > Lymphoid Malignancies > Infectious complications mild and not common in patients receiving CAR-T therapy for diffuse large B cell lymphoma

Infectious complications mild and not common in patients receiving CAR-T therapy for diffuse large B cell lymphoma

Presented By
Dr Roberta Di Blasi, Hospital Saint-Louis, France
Conference
EHA 2019
Trial
JULIET and ZUMA1
Dr Roberta Di Blasi (Hospital Saint-Louis, France) studied infection complications of chimeric antigen receptors T cells (CAR-T) treatment in diffuse large B cell lymphoma (DLBCL) patients [1]. She concluded that febrile neutropenia is a frequent complication and that it can be difficult to distinguish infections from beginning cytokine release syndrome (CRS). Bacterial and viral infection have low incidence and fungal infections did not occur in this cohort at all. Infectious complications appear mild and not fatal. Longer follow-up for immune recovery/infectious complications is needed, as well as broader studies to better define infectious risk in this subset of patients. CAR-T efficacy was demonstrated in DLBCL patients by the JULIET and ZUMA1 trials [2]. Consistent with other CAR-T studies, the main...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on